Frontlight ResearchEarly access
Multiple myeloma trials in Germany
56 of 64 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in GermanyA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Cologne, Essen, Hamburg
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - Phase 3Not yet taking people in GermanyA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Berlin, Dresden, Essen, Hamburg, Leipzig, Munich, Oldenburg
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 - Phase 3Taking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, München, Nuremberg, Würzburg
- Age
- 18 years and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - Phase 3Taking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Freiburg im Breisgau, Hamburg, Tübingen
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - Phase 1/2Taking peopleStudy to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Where
- Heidelberg, Luebeck
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00 - Phase 3Not yet taking people in GermanyA trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Magdeburg, Mainz, Munich, Nuremberg, Wuerzburg
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00 - Phase 1/2SuspendedA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Dresden, Hamburg, Heidelberg
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00 - Phase 1Taking peopleA Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
- Where
- Dresden
- Age
- 18 years and over
- People
- 16
- Run by
- Technische Universität Dresden
See details and how to joinNCT05836896 · EU 2022-502831-20-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Where
- Bamberg, Frankfurt, Hamburg, Hösbach, Karlsruhe, Koblenz, Munich
- Age
- 18 years and over
- People
- 200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00 - Phase 3Active, not recruitingA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- Where
- Berlin, Brunswick, Chemnitz, Munich, Ulm, Wuerzburg
- Age
- 18 years and over
- People
- 893 worldwide
- Run by
- Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00 - No phaseTaking peopleGustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders
- Where
- Munich, Regensburg, Würzburg
- Age
- 18 years and over
- People
- 51
- Run by
- Wuerzburg University Hospital
See details and how to joinNCT07040189 - No phaseTaking peopleGustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
- Where
- Augsburg, Erlangen, München, Regensburg, Würzburg
- Age
- 18 years and over
- People
- 198
- Run by
- Wuerzburg University Hospital
See details and how to joinNCT07649681 - Phase 1/2Not yet taking people in GermanyA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Dresden, Hamburg, Munich, Oldenburg, Wuerzburg
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00 - Phase 1/2Not yet taking people in GermanyA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Berlin, Essen, Heidelberg, Wuerzburg
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 3Not yet taking people in GermanyStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig, Magdeburg, Mainz, München, Nuremberg, Würzburg
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - Phase 3Taking peopleA trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
- Where
- Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz, Nuremberg, Wuerzburg
- Age
- 18 years and over
- People
- 153 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523285-25-00 - Phase 3Not yet taking people in GermanyA Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Where
- Bonn, Cologne, Freiburg im Breisgau, Hanover, Karlsruhe, Tübingen, Ulm, Würzburg
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00 - Phase 1/2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Hamburg, Heidelberg, Munich, Wuerzburg
- Age
- 18 years and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 - Phase 4CompletedElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Chemnitz
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00 - Phase 3Taking peopleGMMG-HD11/DSMM XXI/64007957MMY3010
- Where
- Aachen, Augsburg, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Chemnitz, Cottbus, Dessau-Rosslau, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt, Frankfurt Am Main, Freiburg im Breisgau, Giessen, Göttingen, Greifswald, Hagen, Hamburg, Hannover, Heidelberg, Heilbronn, Jena, Kaiserslautern, Karlsruhe, Kiel, Koblenz, Köln, Leipzig, Ludwigshafen Am Rhein, Magdeburg, Mainz, Mannheim, Marburg, Muenster, Munich, Nürnberg, Oldenburg, Osnabrueck, Potsdam, Regensburg, Schwaebisch Hall, Siegen, Stuttgart, Tuebingen, Ulm, Villingen-Schwenningen, Winnenden, Wuerzburg
- Age
- 18 years to 70 years
- People
- 399
- Run by
- University of Heidelberg Medical Center
See details and how to joinNCT07671287 · EU 2025-523990-40-00 - Phase 1/2Not yet taking people in GermanyEtenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
- Where
- Hamburg
- Age
- 18 years and over
- People
- 220
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07600151 · EU 2025-523049-83-00 - Phase 1/2Taking peopleCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
- Where
- Berlin, Chemnitz, Greifswald, Hamburg, Heidelberg, Luebeck, Ulm
- Age
- 18 years and over
- People
- 45
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT05853965 · EU 2024-511794-30-00 - No phaseTaking peopleBEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
- Where
- Hamburg
- Age
- 18 years and over
- People
- 45
- Run by
- Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT07564219 - Phase 3Active, not recruitingA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Chemnitz, Cologne, Dresden, Hamburg, Hanover, Jena, Luebeck, Mainz, Wuerzburg
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00 - Phase 3Taking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Greifswald, Luebeck, Wuerzburg
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00